Discovery and validation of new potential biomarkers for early detection of colon cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Solé, Xavier ^a,b   Crous Bou, Marta ^a,b   Cordero, David ^a,b   Olivares, David ^a,b   Guinó, Elisabet ^a,b   Sanz Pamplona, Rebeca ^a,b   Rodriguez Moranta, Francisco ^b,c   Sanjuan, Xavier ^b,c   De Oca, Javier ^b,c,d   Salazar, Ramon ^a,b   Moreno, Victor ^a,b,d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; COLLAGEN; COLLAGEN TYPE X ALPHA1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MATRILYSIN; STROMELYSIN; STROMELYSIN 2; TRANSCRIPTION FACTOR MSX2; TUMOR MARKER; UBIQUITIN C; UNCLASSIFIED DRUG; COLLAGEN TYPE 10; TUMOR PROTEIN;

ACTB GENE; ADENOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CA9 GENE; CEL GENE; CLDN2 GENE; COL10A1 GENE; COL11A1 GENE; COLON CANCER; CONTROLLED STUDY; CST1 GENE; CXCL5 GENE; DPT GENE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPHX4 GENE; ESM1 GENE; FAP GENE; FEMALE; GAL GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; JUB GENE; KIAA1199 GENE; LOC100127888 GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MMP10 GENE; MMP3 GENE; MMP7 GENE; MSX2 GENE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SFRP2 GENE; SRPX2 GENE; THBS2 GENE; TNC GENE; TPT1 GENE; UBC GENE; BLOOD; CASE CONTROL STUDY; COLONIC NEOPLASMS; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLLAGEN TYPE X; COLONIC NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84929939552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106748     Document Type: Article

References (57)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
2. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB reports 41: 685-692.
3. Burt RW (2010) Colorectal cancer screening. Current opinion in gastroenterology 26: 466-470.
4. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, et al. (2013) European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 45: 51-59.
5. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, Nicolas D, Moreno SG, et al. (2010) Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. Journal of gastroenterology 45: 703-712.
6. Pawa N, Arulampalam T, Norton JD (2011) Screening for colorectal cancer: established and emerging modalities. Nature reviews Gastroenterology & hepatology 8: 711-722.
7. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, et al. (2006) Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. The New England journal of medicine 355: 1863-1872.
8. Ransohoff DF (2009) How much does colonoscopy reduce colon cancer mortality? Annals of internal medicine 150: 50-52.
9. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, et al. (2012) Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. The New England journal of medicine 366: 697-706.
10. Newton K, Hill J (2010) 5-FU and mismatch repair deficient colorectal cancer: is it time to consider a change in practice? Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 12: 706-707.
11. Ahlquist DA (2010) Molecular detection of colorectal neoplasia. Gastroenterology 138: 2127-2139.
12. Miller S, Steele S (2012) Novel molecular screening approaches in colorectal cancer. Journal of surgical oncology 105: 459-467.
13. Bossuyt PM, Reitsma JB (2003) The STARD initiative. Lancet 361: 71.
14. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, et al. (2006) Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101-2108.
15. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
16. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315.
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome biology 5: R80.
18. Team RDC (2012) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0.
19. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, et al. (2007) A genomewide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 104: 9758-9763.
20. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 848-853.
21. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. (2007) Population genomics of human gene expression. Nature genetics 39: 1217-1224.
22. Zhou B, Xu W, Herndon D, Tompkins R, Davis R, et al. (2010) Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proceedings of the National Academy of Sciences of the United States of America 107: 9923-9928.
23. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY (2010) A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical & experimental metastasis 27: 83-90.
24. LaPointe LC, Dunne R, Brown GS, Worthley DL, Molloy PL, et al. (2008) Map of differential transcript expression in the normal human large intestine. Physiological genomics 33: 50-64.
25. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, et al. (2010) GeneCards Version 3: the human gene integrator. Database: the journal of biological databases and curation 2010: baq020.
26. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research 30: 207-210.
27. Kheirelseid EA, Chang KH, Newell J, Kerin MJ, Miller N (2010) Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC molecular biology 11: 12.
28. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF (2006) Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. American journal of physiology Gastrointestinal and liver physiology 290: G1067-1074.
29. Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer research 64: 5245-5250.
30. Dvinge H, Bertone P (2009) HTqPCR: high-throughput analysis and visualization of quantitative real-time PCR data in R. Bioinformatics 25: 3325-3326.
31. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. The American journal of gastroenterology 103: 1541-1549.
32. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, et al. (2010) Screening for colorectal cancer: randomised trial comparing guaiacbased and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59: 62-68.
33. Peris M, Espinas JA, Munoz L, Navarro M, Binefa G, et al. (2007) Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). Journal of medical screening 14: 81-86.
34. Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi DG, Crous-Bou M, et al. (2014) Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer 13: 46.
35. Warman ML, Abbott M, Apte SS, Hefferon T, McIntosh I, et al. (1993) A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. Nature genetics 5: 79-82.
36. Zheng Q, Zhou G, Morello R, Chen Y, Garcia-Rojas X, et al. (2003) Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. The Journal of cell biology 162: 833-842.
37. Feng Han Q, Zhao W, Bentel J, Shearwood AM, Zeps N, et al. (2006) Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer letters 231: 129-137.
38. Kim H, Watkinson J, Varadan V, Anastassiou D (2010) Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC medical genomics 3: 51.
39. Lascorz J, Forsti A, Chen B, Buch S, Steinke V, et al. (2010) Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. Carcinogenesis 31: 1612-1619.
40. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, et al. (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer research 68: 5206-5215.
41. Chapman KB, Prendes MJ, Sternberg H, Kidd JL, Funk WD, et al. (2012) COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future oncology 8: 1031-1040.
42. Almaawi A, Wang HT, Ciobanu O, Rowas SA, Rampersad S, et al. (2013) Effect of acetaminophen and nonsteroidal anti-inflammatory drugs on gene expression of mesenchymal stem cells. Tissue engineering Part A 19: 1039-1046.
43. Grutzmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, et al. (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3: e3759.
44. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, et al. (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54: 414-423.
45. deVos T, Tetzner R, Model F, Weiss G, Schuster M, et al. (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical chemistry 55: 1337-1346.
46. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, et al. (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124-1132.
47. Korner H, Soreide K, Stokkeland PJ, Soreide JA (2007) Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol 14: 417-423.
48. Hundt S, Haug U, Brenner H (2007) Blood markers for early detection of colorectal cancer: a systematic review. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16: 1935-1953.
49. Bujanda L, Sarasqueta C, Cosme A, Hijona E, Enriquez-Navascues JM, et al. (2013) Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer. PLoS One 8: e51810.
50. Jung K (2008) Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. Br J Cancer 99: 553-554; author reply 555.
51. Alvarez-Chaver P, Otero-Estevez O, Paez de la Cadena M, Rodriguez-Berrocal FJ, Martinez-Zorzano VS (2014) Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol 20: 3804-3824.
52. Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M (2014) Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol 20: 6786-6808.
53. Newton KF, Newman W, Hill J (2012) Review of biomarkers in colorectal cancer. Colorectal Dis 14: 3-17.
54. Tanaka T, Tanaka M, Ishigamori R (2010) Biomarkers for colorectal cancer. Int J Mol Sci 11: 3209-3225.
55. Tjalsma H (2010) Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert review of proteomics 7: 879-895.
56. Diamandis EP (2010) Cancer biomarkers: can we turn recent failures into success? Journal of the National Cancer Institute 102: 1462-1467.
57. Hanash SM, Baik CS, Kallioniemi O (2011) Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nature reviews Clinical oncology 8: 142-150.